Trial results for a Phase 2 study evaluating atezolizumab in combination with platinum-pemetrexed, with or without bevacizumab, for Stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) were posted on ClinicalTrials.gov on 2026-05-12. The study reported median progression-free survival (PFS) of 7.3 months for the cohort including bevacizumab and 7.2 months for the cohort without bevacizumab, in patients with specific mutations progressing after targeted therapies.
Background
The study investigated atezolizumab, an immunotherapy, in combination with platinum (carboplatin or cisplatin) and pemetrexed, with an optional addition of bevacizumab. This combination was explored in patients with Stage IIIB/IV non-squamous non-small cell lung cancer who had specific mutations (EGFR mutations, ALK rearrangement, or ROS1 fusion) and had progressed after prior targeted therapies.
Trial design
The completed Phase 2 study (NCT04042558) enrolled 150 participants with Stage IIIB/IV non-squamous non-small cell lung cancer. Participants had EGFR mutations, ALK rearrangement, or ROS1 fusion and had progressed after targeted therapies. The study evaluated two treatment arms: one receiving carboplatin + pemetrexed + atezolizumab + bevacizumab, and another receiving carboplatin + pemetrexed + atezolizumab.
Key results
The trial reported the following key measurements:
- Objective Response Rate (ORR) According to RECIST 1.1:
- In the Cohort With Bevacizumab, 39 participants achieved an objective response.
- In the Cohort Without Bevacizumab, 33 participants achieved an objective response.
- The Progression-free Survival (PFS):
- For the Cohort With Bevacizumab, the median PFS was 7.3 months (95% Confidence Interval).
- For the Cohort Without Bevacizumab, the median PFS was 7.2 months (95% Confidence Interval).
- The Overall Survival:
- For the Cohort With Bevacizumab, the median overall survival was 17.2 months (95% Confidence Interval).
- For the Cohort Without Bevacizumab, the median overall survival was 16.8 months (95% Confidence Interval).
- The Duration of Response:
- In the Cohort With Bevacizumab, the mean duration of response was 6.25 months (Standard Deviation 3.7).
- In the Cohort Without Bevacizumab, the mean duration of response was 4.60 months (Standard Deviation 3.8).
What this means
The results of this Phase 2 study indicate that both regimens, atezolizumab plus platinum-pemetrexed with or without bevacizumab, showed similar efficacy in patients with Stage IIIB/IV non-squamous NSCLC with specific mutations who had progressed after targeted therapies. The median PFS was nearly identical, at 7.3 months for the bevacizumab-containing arm and 7.2 months for the arm without bevacizumab. Similarly, median overall survival was comparable, at 17.2 months and 16.8 months, respectively. While the mean duration of response was numerically higher in the bevacizumab cohort (6.25 months vs 4.60 months), the overall similarity in PFS and OS suggests that the addition of bevacizumab may not provide substantial additional benefit for these specific outcomes in this patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04042558, titled "A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies", were posted on 2026-05-12 on clinicaltrials.gov.